US OptionsDetailed Quotes
ADPT241220P5000
- 0.38
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.00High0.00Low
0.38Open0.38Pre Close0 Volume2 Open Interest5.00Strike Price0.00Turnover38.50%IV1.49%PremiumDec 20, 2024Expiry Date0.31Intrinsic Value100Multiplier25DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type-0.7123Delta0.7328Gamma12.34Leverage Ratio-0.0028Theta-0.0021Rho-8.79Eff Leverage0.0042Vega
Adaptive Biotechnologies Stock Discussion
Sign in to post a comment
$Adaptive Biotechnologies (ADPT.US)$
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that its clonoSEQ® test has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union. This makes clonoSEQ the first IVDR-certified test for detecting minimal residual disease (MRD) in patients with lymphoid malignancies. The certification allows for broad use in assessing MRD status and chang...
2
2
Good volume move up. Small caps like adaptive biotechnologies are moving after Nvidia and other big techs took a break.
Should see higher prices from here.
Should see higher prices from here.
3
$Adaptive Biotechnologies (ADPT.US)$ Adaptive Biotechnologies Says Its Next-generation Sequencing-based ClonoSEQ Test For Measurable Residual Disease Assessment Will Be Included In Several Oral And Poster Presentations At American Society Of Clinical Oncology Annual Meeting
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually...
The meeting will be taking place from May 31-June 4 in Chicago. Company will also present at the European Hematology Association (EHA) Hybrid Congress taking place June 13-16 in Madrid and virtually...
1
Will they be as good as Ardelyx? Hopefully.
Ardelyx price skyrocketed after good earnings. The tide could be turning for biopharm, biotech stocks.
Ardelyx price skyrocketed after good earnings. The tide could be turning for biopharm, biotech stocks.
Recent insider selling at Adaptive Biotechnologies and lack of insider buying in the past year may deter potential investors, despite insiders owning significant shares.
$Adaptive Biotechnologies (ADPT.US)$ Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene's Lymphoid Malignancy Pipeline
3
Recent months saw no insider buying and some selling, potentially raising investor concerns. Lack of recent insider buying combined with sales might demand investor caution.
QUICK SCALP 10 $ADPT — STOCK & OPTION PLAY
ALERT ON: $10.02
ON THE WATCH: $10.10
🥇 SIGNED OF MORE UPTREND: $10.25
NEED IT TO BREAK OVER: $10.36
key indicator for MORE uptrend: $10.42
confirmation uptrend - $10.63
mini breakout - $10.71. $Adaptive Biotechnologies (ADPT.US)$
ALERT ON: $10.02
ON THE WATCH: $10.10
🥇 SIGNED OF MORE UPTREND: $10.25
NEED IT TO BREAK OVER: $10.36
key indicator for MORE uptrend: $10.42
confirmation uptrend - $10.63
mini breakout - $10.71. $Adaptive Biotechnologies (ADPT.US)$
1
Upgrades
• $Ciena (CIEN.US)$: B.Riley Upgrades to Buy from Neutral - PT $67 (from $65)
• $Ecolab (ECL.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $195 (from $180)
• $Hersha Hospitality Trust (HT.US)$: Jefferies Upgrades to Buy from Neutral - PT $13 (from $11)
• $Martin Marietta Materials (MLM.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $410 (from $420)
• $Portland General Electric (POR.US)$: Goldman Sachs Upgrades to Buy from Neutral - P...
• $Ciena (CIEN.US)$: B.Riley Upgrades to Buy from Neutral - PT $67 (from $65)
• $Ecolab (ECL.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $195 (from $180)
• $Hersha Hospitality Trust (HT.US)$: Jefferies Upgrades to Buy from Neutral - PT $13 (from $11)
• $Martin Marietta Materials (MLM.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $410 (from $420)
• $Portland General Electric (POR.US)$: Goldman Sachs Upgrades to Buy from Neutral - P...
16
2
$ARK Innovation ETF (ARKK.US)$ $ARK Next Generation Internet ETF (ARKW.US)$ $ARK Autonomous Technology & Robotics ETF (ARKQ.US)$
Investment star Cathie Wood, Chief Executive of Ark Investment Management, continues her buying and selling of stocks -- mostly buying -- amid the equity market’s turmoil.
On Friday, she ventured into 3D printer companies, $Stratasys (SSYS.US)$ and $Velo3D (VLD.US)$. Ark also continued its foray into biotechnology stoc...
Investment star Cathie Wood, Chief Executive of Ark Investment Management, continues her buying and selling of stocks -- mostly buying -- amid the equity market’s turmoil.
On Friday, she ventured into 3D printer companies, $Stratasys (SSYS.US)$ and $Velo3D (VLD.US)$. Ark also continued its foray into biotechnology stoc...
3
No comment yet
MARKET-TEST-DUMMY : Possibly going right direction
MARKET-TEST-DUMMY MARKET-TEST-DUMMY : or it will fizzle